Squarepoint Ops LLC decreased its position in shares of Simulations Plus, Inc. (NASDAQ:SLP - Free Report) by 40.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,655 shares of the technology company's stock after selling 58,282 shares during the quarter. Squarepoint Ops LLC owned about 0.42% of Simulations Plus worth $1,550,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in Simulations Plus by 26.0% during the second quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company's stock worth $52,000 after buying an additional 585 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Simulations Plus by 59.3% during the first quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company's stock worth $53,000 after acquiring an additional 1,669 shares in the last quarter. Fifth Third Bancorp acquired a new stake in shares of Simulations Plus in the 1st quarter worth about $54,000. Caitong International Asset Management Co. Ltd lifted its position in Simulations Plus by 343.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company's stock valued at $73,000 after acquiring an additional 3,084 shares in the last quarter. Finally, Longfellow Investment Management Co. LLC bought a new position in Simulations Plus in the 2nd quarter valued at about $77,000. 78.08% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts have recently commented on SLP shares. William Blair downgraded Simulations Plus from an "outperform" rating to a "market perform" rating in a research note on Wednesday, June 17th. Craig Hallum downgraded Simulations Plus from a "buy" rating to a "hold" rating and set a $18.50 price target for the company. in a report on Thursday, June 18th. Weiss Ratings raised Simulations Plus from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, July 10th. Finally, Wall Street Zen cut Simulations Plus from a "buy" rating to a "hold" rating in a research note on Saturday, June 13th. Seven analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Reduce" and an average price target of $17.25.
Check Out Our Latest Stock Report on Simulations Plus
Simulations Plus Trading Down 0.1%
Simulations Plus stock opened at $18.41 on Wednesday. The business's 50 day simple moving average is $18.34 and its 200 day simple moving average is $15.95. Simulations Plus, Inc. has a 12 month low of $11.09 and a 12 month high of $21.01. The company has a market cap of $372.43 million, a price-to-earnings ratio of 46.02 and a beta of 1.33.
Simulations Plus (NASDAQ:SLP - Get Free Report) last issued its earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.07. Simulations Plus had a return on equity of 13.50% and a net margin of 9.88%.The firm had revenue of $21.89 million for the quarter, compared to analyst estimates of $20.90 million.
Insider Buying and Selling
In other Simulations Plus news, Director Walter Woltosz sold 4,177 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total transaction of $77,023.88. Following the completion of the transaction, the director owned 3,202,131 shares in the company, valued at $59,047,295.64. This trade represents a 0.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.10% of the stock is currently owned by company insiders.
Simulations Plus Company Profile
(
Free Report)
Simulations Plus, Inc develops software and provides consulting services for pharmaceutical and biotechnology companies involved in drug discovery and development. Its modeling and simulation tools are designed to help researchers evaluate drug candidates, understand how medicines move through the body, assess safety risks and support decisions throughout the development process.
The company's products include GastroPlus, a platform used for physiologically based pharmacokinetic and biopharmaceutic modeling; ADMET Predictor, which helps predict absorption, distribution, metabolism, excretion and toxicity characteristics; and DILIsym, a software platform focused on drug-induced liver injury.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Simulations Plus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Simulations Plus wasn't on the list.
While Simulations Plus currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.